Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

References

• Oettgen HF, Old LJ, Boyse EA, et al Inhibition of leukemias in man by L-asparaginase. Cancer Res 1967;27:2619–2631.
   PubMed Web of Science ®Google Scholar
• Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E 3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601–5607.
   PubMed Web of Science ®Google Scholar
• Haley EE, Fischer GA, Welch AD. The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res 1961;21:532–536.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Park JR, Thomson BG, et al Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335–5341.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, et al Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103–111.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998;12:1527–1533.
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525–1532.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217–226.
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931–936.
   PubMed Web of Science ®Google Scholar
• Killander D, Dohlwitz A, Engstedt L, et al Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220–228.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780–1786.
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Bertino JR, Skeel RT, et al L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893–901.
   PubMed Web of Science ®Google Scholar
• Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660–665.
   PubMed Web of Science ®Google Scholar
• Wang B, Hak LJ, Relling MV, Pui CH, Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods 2000;239:75–83.
   PubMed Web of Science ®Google Scholar
• Orsonneau JL, Brassart EA, Lecame M, Thomare P, Delaroche O, Dudouet D. Automated kinetic assay of plasmatic L-asparaginase activity undergoing therapy for acute lymphoblastic leukemia. Ann Biol Clin (Paris) 2004;62:568–572.
   PubMed Web of Science ®Google Scholar
• Boos J, Werber G, Ahlke E, et al Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544–1550.
   PubMed Web of Science ®Google Scholar
• Land VJ, Sutow WW, Fernbach DJ, et al Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972;30:339–347.
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Weil M, Bussel A, et al Treatment of acute leukemia with L-asparaginase–preliminary results on 84 cases. Recent Results Cancer Res 1970;33:263–278.
   PubMedGoogle Scholar
• Evans WE, Tsiatis A, Rivera G, et al Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378–1383.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99–104.
   PubMedGoogle Scholar
• Nesbit M, Chard R, Evans A, et al Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9–13.
   PubMedGoogle Scholar
• Jaffe N, Traggis D, Das L, et al L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971;31:942–949.
   PubMed Web of Science ®Google Scholar
• Lei Y, PanettaYang L, Panetta JC, et al Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932–1939.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, Loning L, et al Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794–799.
   PubMed Web of Science ®Google Scholar
• Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675–681.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schrøder H, Ingerslev J, et al Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983–990.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Holcenberg JS, Glaubiger DL, et al L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554–4558.
   PubMed Web of Science ®Google Scholar
• Appel IM, Pinheiro JP, den Boer ML, et al Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254–2256.
   PubMed Web of Science ®Google Scholar
• Jarrar M, Gaynon PS, Periclou AP, et al Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141–146.
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Schrøder H, Jakobsen P, Müller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001;52:433–437.
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049–1057.
   PubMed Web of Science ®Google Scholar
• Hak LJ, Relling MV, Cheng C, Pei D, Wang B, Sandlund JT. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004;18:1072–1077.
   PubMed Web of Science ®Google Scholar